Stal­ler­genes Greer's dust mite al­ler­gy drug clears piv­otal study, edges clos­er to ap­proval

In a bid to tack­le one of the most com­mon al­ler­gens that asth­ma pa­tients are sen­si­tive to, Stal­ler­genes Greer’s house dust mite im­munother­a­py is one step clos­er to win­ning ap­proval af­ter re­port­ing suc­cess­ful late-stage da­ta on Tues­day.

The Lon­don-based al­ler­gy biotech said its sub­lin­gual tablet STA­GR320 pro­voked a sta­tis­ti­cal­ly sig­nif­i­cant re­duc­tion in house dust mite(HDM)-in­duced al­ler­gic rhini­tis symp­toms (p<0.0001) against a place­bo, meet­ing the main goal of the study.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER